Compare Biogen Inc (BIIB) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Biogen Inc trades at $207.29 (market cap $30.13B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.68. The key difference: Biogen Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | VTIP | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | — |
52-Week High | $216.63 | $50.75 |
52-Week Low | $128.93 | $49.39 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
VTIP trades at $49.695 with minimal daily movement (+0.03%). Technical indicators show a neutral overall signal with bearish moving averages, while RSI readings suggest balanced momentum. The ETF focuses on short-term inflation-protected securities, offering protection against rising costs with current inflation projections around 3.8%. Recent institutional buying includes 55 North Private Wealth increasing holdings by 12.2%.
VTIP provides inflation hedging with expected returns slightly above comparable treasuries. The Fed's stance against rate cuts in 2026 supports short-term TIPS, though inflation volatility remains a key risk. Analyst sentiment is cautiously positive given the inflation environment, making VTIP a strategic defensive holding for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
